PTC Therapeutics (NASDAQ: PTCT) saw its stock price plummet by 11.37% in intraday trading on Tuesday, following the release of its first-quarter earnings report and amid lukewarm analyst ratings. The significant drop suggests investors may have been disappointed with the company's financial performance or future outlook.

The biopharmaceutical company reported a net income of $866.562 million for Q1, along with product revenue of $153.426 million. While these figures represent the company's financial performance, the market's negative reaction indicates that they may have fallen short of investor expectations or revealed concerning trends.

Adding to the downward pressure, analysts from major financial institutions maintained their cautious stance on PTC Therapeutics. Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on PTCT, citing mixed clinical results and uncertain FDA approval prospects. Similarly, Scotiabank analyst Louise Chen maintained a Hold rating with a price target of $55.00. These neutral ratings, combined with the earnings release, appear to have dampened investor enthusiasm, contributing to the sharp decline in stock price.